Operating characteristics of a Simon two-stage phase II clinical trial design incorporating continuous toxicity monitoring

Authors

  • H.E. Ray,

    Corresponding author
    1. Department of Mathematics and Statistics, Kennesaw State University, Kennesaw, GA, USA
    • Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences, University of Louisville, Louisville, KY, USA
    Search for more papers by this author
  • S.N. Rai

    1. Biostatistics Shared Facility, JG Brown Cancer Center and Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY, USA
    Search for more papers by this author

H. E. Ray, Department of Mathematics and Statistics, Kennesaw State University, Kennesaw, GA, USA.

E-mail: hray8@kennesaw.edu

Abstract

Phase II clinical trials are usually designed to measure efficacy, but safety is also an important end point. Previous authors recommended a method to monitor toxic events after each patient is enrolled, which is also known as continuously monitoring the toxicity. In this work, we investigate combining the usual Simon two-stage design to monitor response with the continuous toxicity monitoring methodology. Theoretical justification is given for the nominal size, probability of early termination, and average sample size under the null hypothesis of the combined testing procedure. A series of simulations are performed to investigate the performance of the combined procedure. Copyright © 2012 John Wiley & Sons, Ltd.

Ancillary